|
|
Volumn 8, Issue 4, 2015, Pages 493-494
|
|
FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
FLUORODEOXYGLUCOSE F 18;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
INTERLEUKIN 6;
MALONALDEHYDE;
MLDL 1278A;
OXIDIZED LOW DENSITY LIPOPROTEIN;
OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;
PLACEBO;
TUMOR NECROSIS FACTOR ALPHA;
UNCLASSIFIED DRUG;
BIOLOGICAL MARKER;
LOW DENSITY LIPOPROTEIN;
MLDL1278A;
MONOCLONAL ANTIBODY;
RADIOPHARMACEUTICAL AGENT;
RECOMBINANT PROTEIN;
ANTIINFLAMMATORY ACTIVITY;
AORTA ATHEROSCLEROSIS;
CAROTID ATHEROSCLEROSIS;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
IMMUNOGENICITY;
LETTER;
MACROPHAGE MIGRATION INHIBITION;
MULTICENTER STUDY (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ANTAGONISTS AND INHIBITORS;
ATHEROSCLEROSIS;
BLOOD;
CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
FEMALE;
MALE;
MIDDLE AGED;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
POSITRON EMISSION TOMOGRAPHY;
PROCEDURES;
RANDOMIZED CONTROLLED TRIAL;
SCINTISCANNING;
ANTIBODIES, MONOCLONAL;
ATHEROSCLEROSIS;
BIOMARKERS;
DOUBLE-BLIND METHOD;
FEMALE;
FLUORODEOXYGLUCOSE F18;
HUMANS;
LIPOPROTEINS, LDL;
MALE;
MIDDLE AGED;
POSITRON-EMISSION TOMOGRAPHY;
RADIOPHARMACEUTICALS;
RECOMBINANT PROTEINS;
|
|
EID: 84928124939
PISSN: 1936878X
EISSN: 18767591
Source Type: Journal
DOI: 10.1016/j.jcmg.2014.06.021 Document Type: Letter |
|
Times cited : (73)
|
|
References (3)
|
